{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-23+Therapy&page=2",
    "query": {
      "intervention": "IL-23 Therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-23+Therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T17:44:27.648Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04271540",
      "title": "MIcrovascular dysfuNction In Moderate-severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Tildrakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marcelo F. Di Carli, MD, FACC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-04-04",
      "completion_date": "2024-07-17",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04271540"
    },
    {
      "nct_id": "NCT06563323",
      "title": "Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pyoderma Gangrenosum",
        "Skin Diseases",
        "Wound Heal",
        "Pyoderma",
        "Skin Ulcer"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 17,
      "start_date": "2025-02-01",
      "completion_date": "2027-08-13",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Portland, Oregon",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06563323"
    },
    {
      "nct_id": "NCT03690544",
      "title": "Apremilast for RAS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Recurrent Aphthous Stomatitis"
      ],
      "interventions": [
        {
          "name": "Apremilast 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-10-12",
      "completion_date": "2021-07-14",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03690544"
    },
    {
      "nct_id": "NCT05283135",
      "title": "High Dose Risankizumab for Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Medical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-03-01",
      "completion_date": "2024-07-10",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283135"
    },
    {
      "nct_id": "NCT01369355",
      "title": "A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease",
        "Colitis",
        "IBD",
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg SC q8w",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 130 mg IV",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg SC q12w",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 1282,
      "start_date": "2011-09-13",
      "completion_date": "2019-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 77,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Carlos",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369355"
    },
    {
      "nct_id": "NCT00267969",
      "title": "A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor Research & Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 766,
      "start_date": "2005-12",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2013-06-17",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267969"
    },
    {
      "nct_id": "NCT03556202",
      "title": "A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1936,
      "start_date": "2018-09-03",
      "completion_date": "2022-02-07",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03556202"
    },
    {
      "nct_id": "NCT07121920",
      "title": "Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "IBD (Inflammatory Bowel Disease)",
        "IBD",
        "IBD - Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Confocal Laser Endomicroscopy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cook Children's Health Care System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-01",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 2,
      "location_summary": "Arlington, Texas • Fort Worth, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07121920"
    },
    {
      "nct_id": "NCT07502339",
      "title": "Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "UC - Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-10-15",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07502339"
    },
    {
      "nct_id": "NCT05110313",
      "title": "Effects of Tildrakizumab on Epigenetic Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis",
        "Aging",
        "Epigenetic Disorder",
        "Inflammation; Skin"
      ],
      "interventions": [
        {
          "name": "TILDRAKIZUMAB",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Carlos Wambier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-04-08",
      "completion_date": "2024-05-27",
      "has_results": false,
      "last_update_posted_date": "2024-07-18",
      "last_synced_at": "2026-09-27T17:44:27.648Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05110313"
    }
  ]
}